Table 2.
Frequencies of AEs in patients with CHB and CHC after Peg-IFN-based therapy
| AEs | Frequencies of AEs, n/N (%) | |||||
|---|---|---|---|---|---|---|
| 24 weeks | 48 weeks | |||||
| CHB | CHC | P | CHB | CHC | P | |
| Pyrexia | 12/56 (21.4%) | 18/103 (17.5%) | 0.543 | 7/25 (28.0%) | 11/46 (23.9%) | 0.705 |
| Flulike syndrome | 39/56 (69.6%) | 78/103 (75.7%) | 0.406 | 22/25 (88.0%) | 34/46 (73.9%) | 0.228 |
| Oral symptoms | 20/56 (35.7%) | 63/103 (61.2%) | 0.002* | 16/25 (64.0%) | 32/46 (69.6%) | 0.632 |
| Diarrhea | 8/56 (14.3%) | 19/103 (18.5%) | 0.504 | 5/25 (20.0%) | 11/46 (23.9%) | 0.706 |
| Gastrointestinal upset | 18/56 (32.1%) | 53/103 (51.5%) | 0.019* | 11/25 (44.0%) | 24/46 (52.2%) | 0.511 |
| Injection site inflammation | 2/56 (3.56%) | 10/103 (9.7%) | 0.217 | 1/25 (4.0%) | 5/46 (10.9%) | 0.414 |
| Blurred vision | 2/56 (3.6%) | 19/103 (18.5%) | 0.012* | 3/25 (12.0%) | 16/46 (34.8%) | 0.050* |
| Hearing impairment | 1/56 (1.8%) | 3/103 (2.9%) | 1.000 | 2/25 (8.0%) | 3/46 (6.5%) | 1.000 |
| Anxiety | 8/56 (14.3%) | 38/103 (36.9%) | 0.003* | 7/25 (28.0%) | 19/46 (41.3%) | 0.266 |
| Depression | 1/56 (1.8%) | 27/103 (26.2%) | <0.0001* | 0/25 (0.0%) | 18/46 (39.1%) | <0.0001* |
| Insomnia | 16/56 (28.6%) | 62/103 (60.2%) | <0.0001* | 9/25 (36.0%) | 31/46 (67.4%) | 0.011* |
| Neurologic syndrome | 7/56 (12.5%) | 45/103 (43.7%) | <0.0001* | 4/25 (16.0%) | 32/46 (69.6%) | <0.0001* |
| Alopecia | 20/56 (35.7%) | 69/103 (67.0%) | <0.0001* | 11/25 (44.0%) | 34/46 (73.9%) | 0.012* |
| Palpitations | 2/56 (3.6%) | 34/103 (33.0%) | <0.0001* | 1/25 (4.0%) | 15/46 (32.6%) | 0.006* |
| Skin manifestations | 15/56 (26.8%) | 57/103 (55.3%) | 0.001* | 14/25 (56.0%) | 31/46 (67.4%) | 0.341 |
| Breathlessness | 2/56 (3.6%) | 45/103 (43.7%) | <0.0001* | 0/25 (0.0%) | 21/46 (45.7%) | <0.0001* |
* Statistically significant